Neumora Therapeutics discontinued navacaprant after both Koastal-2 and Koastal-3 Phase 3 studies failed to achieve statistical significance on primary or key secondary endpoints in major depressive disorder. The company said navacaprant did not outperform placebo on change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores by week 6, including a placebo-favorable result in Koastal-3. Neumora plans to lay off roughly 35% of staff to target $10 million in annual savings. With the asset shelved, the company said its remaining pipeline includes NMRA-511 for Alzheimer’s disease agitation, NMRA-898 for schizophrenia, and NMRA-215 for obesity, and it projected a cash runway into the third quarter of 2027.